James Maitland is a leading expert in the intersection of healthcare technology and data analytics, specializing in how real-time insights can transform legacy pharmacy benefit management systems. With a background rooted in leveraging advanced IoT and robotics for medical applications, he brings a unique perspective to the challenges of PBM transparency and operational efficiency. His work focuses on dismantling the barriers of traditional reporting to foster a more collaborative and data-driven healthcare ecosystem.
The conversation explores the shift from retrospective to real-time data in the PBM industry, highlighting how immediate visibility into drug spend and utilization can prevent cost spikes and strengthen client relationships. Maitland delves into the risks of delayed reporting, the power of self-service analytics, and the ways transparency is becoming a non-negotiable standard for modern payers.
Legacy PBM reporting often arrives 30 to 90 days after the fact. How do these delays specifically impact the trust between PBMs and clients, and what operational risks arise when utilization shifts or cost spikes are identified months late?
When a client receives data that is 30, 60, or even 90 days old, they are essentially performing an autopsy on their budget rather than managing it in real-time. This delay creates a massive gap where trust begins to erode because the client feels they are reacting to problems that have already solidified into financial losses. Operationally, this is incredibly risky; by the time a cost spike is identified, the capital has already left the building and the utilization patterns have become entrenched. You cannot course-correct a patient’s therapy or address a performance guarantee shortfall when the window for intervention closed two months prior. It transforms the PBM-client relationship from a partnership into a cycle of explanations and apologies, which is a primary driver of client churn.
Identifying a single high-cost drug or a specific prescriber driving spend can be difficult with traditional reporting cycles. How do real-time insights allow PBMs to intervene in these scenarios, and what step-by-step actions should be taken when a cost spike is detected?
Real-time insights act like a diagnostic sensor, flagging anomalies as they happen rather than after the billing cycle ends. In one notable instance, we saw a client discover that a single high-cost drug—which actually had viable generic alternatives—was being funneled through one specific prescriber and one pharmacy, driving a disproportionate share of their total spend. When a spike like this is detected, the first step is to use an analytics platform to isolate the NDC, the prescriber, and the pharmacy location to see if it’s a localized trend. Next, the PBM must immediately evaluate if there are lower-cost clinical alternatives or if a prior authorization adjustment is needed. Finally, they can engage the client with a solution in hand, often within hours of the initial claim, rather than waiting for a quarterly review to realize they’ve overspent by thousands of dollars.
Shifting from retrospective reports to real-time visibility often moves client conversations from escalatory to collaborative. What does a “proactive” check-in look like in practice, and how do self-service analytics platforms change the way clients perceive their dependency on a PBM?
A proactive check-in feels less like a formal audit and more like a tactical huddle. Instead of a tense meeting focused on “why did our costs jump 15% last quarter?”, the conversation becomes, “we noticed a slight uptick in this specialty category this week, and here is how we are managing it.” This shifts the tone from escalatory to forward-looking, where both parties are working on the same side of the table. Self-service platforms like RxIQ BI are revolutionary because they empower the client to see the adjudication data for themselves without waiting for a middleman. When clients have that direct visibility, they no longer feel helplessly dependent on the PBM to tell them the truth; they see the data as it unfolds, which actually builds a deeper, more mature level of trust.
With a small number of PBMs managing nearly 95% of prescriptions, transparency has become a major differentiator. How can PBMs use immediate data access to reduce churn, and what specific anecdotes highlight the value of letting clients see the adjudication data for themselves?
In a market where a few giants control 95% of the volume, transparency is the only way for a PBM to truly stand out. We’ve seen clients who were considering becoming their own PBMs because they felt they lacked control, but once they were given direct, real-time access to the adjudication platform, their entire perspective changed. They were amazed by how quickly opportunities for savings surfaced—sometimes within the first few days of onboarding. By showing the “math” behind the claims immediately, the PBM proves its value daily rather than just during the annual renewal period. This level of openness makes it much harder for a client to leave because they have become accustomed to a level of clarity that legacy providers simply aren’t offering.
Regulatory pressure and rising drug costs have narrowed the tolerance for opaque insights. In what ways does providing direct access to data during onboarding strengthen a long-term relationship, and what metrics best prove the value of this transparency to a skeptical payer?
Providing direct data access during onboarding sets a “cards-on-the-table” tone that is vital for long-term loyalty. It signals to the payer that the PBM has nothing to hide and is confident in its ability to manage costs efficiently from day one. To a skeptical payer, the most convincing metrics aren’t just the final spend numbers, but the “speed to insight”—how many days it takes to identify and resolve a cost outlier. When you can show a client that you caught a wasteful utilization trend in 24 hours versus 90 days, you are demonstrating a tangible preservation of their capital. This transparency effectively de-risks the relationship for the payer, making them much more likely to stay through various market fluctuations.
What is your forecast for the role of real-time data in PBM client retention?
I believe that within the next few years, real-time data will move from being a “value-add” to a baseline requirement for any PBM that wants to survive. As drug prices continue to climb and regulatory oversight tightens, the era of the 90-day reporting lag is coming to an end. We will see a shift toward “living contracts,” where performance guarantees are monitored in real-time and adjustments are made monthly or even weekly. PBMs that embrace this radical transparency will see significantly higher retention rates, while those clinging to legacy, opaque reporting structures will find it increasingly difficult to justify their fees to savvy, data-hungry payers. In short, the future of PBM retention isn’t just about who has the lowest rebates, but who provides the clearest, fastest view of the truth.
